What are the findings from the SURPASS-CVOT trial?
Read the latest reports from EASD 2025, suggesting tirzepatide is noninferior to dulaglutide for protecting against cardiovascular events in people with type 2 diabetes and atherosclerotic cardiovascular disease.
@exploregh @Ganyo_Bi_Nii@ewepride Your submission is faulty. Wasnβt about becoming a king. It was about releasing the Ga stool to the Ga people, which Ayi refused to return. Please do your research well, before submitting.